The UK research landscape
Around 4.6 million people in the UK now have a recorded diabetes diagnosis, and roughly one in five adults is living with diabetes or prediabetes. With numbers like these, research has never been busier. NHS trusts, universities and commercial sponsors run hundreds of diabetes clinical trials across England, Scotland, Wales and Northern Ireland, testing everything from weight-loss programmes and new drug classes to nerve-damage screening and hybrid closed-loop insulin systems.
The field shifted noticeably in early 2026 when NICE updated its NG28 guidance, recommending SGLT-2 inhibitors alongside modified-release metformin for most newly diagnosed type 2 patients. Behind that kind of policy change sits years of trial data, much of it gathered from UK participants.
For people living with diabetes, the practical questions stay the same: what will I actually have to do, is it safe, and will it cost me anything? The answers depend heavily on the type of trial. Another barrier is awareness. GPs are stretched, waiting rooms rarely advertise studies, and the phrase "clinical trial" still makes many people picture guinea pigs and unknown risks.
What kinds of trials are recruiting
Some of the most visible studies are remission trials. The Edinburgh Diabetes Remission Study, run by NHS Lothian and the University of Edinburgh, is currently recruiting four groups of participants aged 45 to 79 with a BMI between 30 and 45. Everyone follows an 800-calorie-a-day total diet replacement for eight to twelve weeks, then receives dietary support for up to a year. The goal is to understand exactly how weight loss reverses fat accumulation in the pancreas and restores insulin secretion.
Other trials focus on new medications. The AZP-531 study, advertised through diabetes.co.uk, is testing whether a new drug can lower blood sugar without the hypoglycaemia that many current treatments cause. It involves a 17-night inpatient stay and pays £3,875 plus travel expenses for eligible adults aged 18 to 65 with type 2 diabetes.
Then there are trials targeting complications. Sheffield Teaching Hospitals is running its enhanced diabetes care process, screening people with type 2 diabetes for early nerve damage and testing whether intensified care can halt or reverse it. Participants attend the Royal Hallamshire or Northern General hospitals for questionnaires, blood and urine tests, and an optional skin biopsy.
Type 1 research is equally active. Breakthrough T1D UK lists studies across Cardiff, Liverpool, Essex and Ulster, including an alpha-MSH hormone study at Ulster University that pays £100 to £200 per visit for adults aged 18 to 50.
| Trial type | UK example | What it involves | Best suited to | Main advantages | What to watch for |
|---|
| Remission and weight loss | Edinburgh Diabetes Remission Study (NHS Lothian) | 8-12 weeks of 800 kcal/day meal replacement, follow-up to 12 months | Adults 45-79 with type 2 diabetes, BMI 30-45 | Medically supervised, no experimental drug | Demanding diet schedule |
| New medication safety | AZP-531 trial (diabetes.co.uk listing) | 17-night inpatient stay, glucose sensor, repeated tests | Adults 18-65 with type 2 diabetes on metformin | Compensation plus travel expenses | Strict eligibility and lifestyle rules |
| Complication screening | Sheffield enhanced diabetes care | Screening visits, nerve questionnaires, optional skin biopsy | People with type 2 diabetes and early nerve damage | Early detection of neuropathy | Extra hospital appointments |
| Type 1 diabetes studies | Alpha-MSH study, Ulster University | Two to four hour visits, blood samples, optional muscle biopsy | Adults 18-50 with or without type 1 diabetes | Supports future treatments, paid | Travel to the Coleraine campus |
What taking part really looks like
Every UK trial must pass ethical review before it recruits. Participants receive detailed information sheets, can withdraw at any time without affecting their routine diabetes care, and most NHS studies cover reasonable travel costs. That said, it pays to understand the difference between an academic trial hosted by an NHS trust and a commercial trial run by a private research unit. Commercial studies tend to offer higher compensation but often come with stricter rules, as the AZP-531 example shows.
Eligibility can feel frustratingly specific. The Edinburgh study is limited to certain age and BMI ranges, while the Sheffield trial excludes people with other forms of diabetes. This is not bureaucracy for its own sake; it keeps results clean and protects participants.
A typical participant in a remission trial might be in her late fifties, living near Edinburgh, managing type 2 diabetes for four years. Her HbA1c has crept up despite metformin, and her consultant mentions the study at a routine appointment. After a screening visit covering blood tests and health history, she is accepted. The first month of meal replacements is hard, but she is reviewed regularly by a specialist nurse and dietitian. By the end she has lost more than ten kilograms, and her follow-up bloodwork shows clear improvement. She tells friends it was the most structured support she has ever received from the NHS.
Not every story ends in remission, and trials carry risks that must be explained honestly. But for many people, taking part means access to care that standard appointments simply cannot offer: continuous glucose monitoring, extra scans, specialist reviews and dietetic input.
How to find and join a trial
- Start with your GP or hospital diabetes team. They can check local research registers and may refer you directly.
- Search the NIHR Be Part of Research website, which lists NHS trials across the UK with plain-English summaries.
- Check ClinicalTrials.gov and the ISRCTN registry for study records, eligibility criteria and contact details.
- Look at condition-specific organisations. Diabetes UK and Breakthrough T1D UK both maintain research pages, and diabetes.co.uk lists paid studies such as the AZP-531 trial.
- Before you agree to anything, ask: how many visits, where, who covers travel, whether compensation is offered, how your usual care continues, and what happens if you withdraw.
Research is concentrated in certain cities, but you do not have to live in one to benefit. Edinburgh, Sheffield, Cardiff, Liverpool and Coleraine all host active studies, and many trials now include remote questionnaires and online follow-ups. If no suitable trial is open near you, ask to be added to a research register at your local NHS trust. Practices across the UK are encouraged to flag research opportunities during annual diabetes reviews, so raising the topic at your next appointment is a sensible move.
Final thoughts
Diabetes research in the UK is entering an interesting phase. Remission studies are changing what doctors tell newly diagnosed patients, new drug classes are altering first-line treatment, and technology trials are improving everyday management for people with type 1 diabetes. None of this happens without volunteers.
You do not need a science background to take part, and you do not need to accept every study that comes your way. The first step is simply asking your care team what research is running locally and reading one or two trial summaries that match your situation. If a study looks right, the screening process will tell you quickly whether you qualify. If it does not, other trials and other opportunities will come along. The register is open, the studies are recruiting, and the next breakthrough could start with a conversation at your next diabetes review.
研究の知恵